In addition, several MEK/ERK inhibitors such as BVD-523, CC-90003, FCN-159, refametinib, SHR7390, E6201, CC-90003, KO-947, TAK-733, AZD8330, and LY3214996 are currently in clinical trials for treating pancreatic adenocarcinoma, breast cancer, BRAF-mutant colorectal cancer, hepatocellular cancer, metastatic melanoma, non-small-cell lung cancer, and NB [22]. This evidence concerns the gene MAP2K7 and breast carcinoma.